These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38000668)

  • 1. Performance characteristics of Allele-Specific PCR (ASPCR) in detecting drug resistance mutations among non-B HIV-1 Variants.
    Adawaye C; Fokam J; Kamangu EN; Ngwese DTA; Susin F; Moussa AM; Hig-Zounet B; Mad-Toingué J; Tidjani A; Vaira D; Moutschen M
    J Virol Methods; 2024 Jan; 323():114856. PubMed ID: 38000668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of 454 Ultra-Deep Sequencing and Allele-Specific Real-Time PCR with Regard to the Detection of Emerging Drug-Resistant Minor HIV-1 Variants after Antiretroviral Prophylaxis for Vertical Transmission.
    Hauser A; Kuecherer C; Kunz A; Dabrowski PW; Radonić A; Nitsche A; Theuring S; Bannert N; Sewangi J; Mbezi P; Dugange F; Harms G; Meixenberger K
    PLoS One; 2015; 10(10):e0140809. PubMed ID: 26469189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allele-specific real-time PCR testing for minor HIV-1 drug resistance mutations: assay preparation and application to reveal dynamic of mutations in vivo.
    Guo DX; Li HP; Li L; Zhuang DM; Jiao LY; Wang Z; Bao ZY; Liu SY; Liu YJ; Li JY
    Chin Med J (Engl); 2010 Dec; 123(23):3389-95. PubMed ID: 22166519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection and quantification of minor human immunodeficiency virus type 1 variants harboring K103N and Y181C resistance mutations in subtype A and D isolates by allele-specific real-time PCR.
    Hauser A; Mugenyi K; Kabasinguzi R; Bluethgen K; Kuecherer C; Harms G; Kunz A
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2965-73. PubMed ID: 19433556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal Detection and Persistence of Minority Drug-Resistant Populations and Their Effect on Salvage Therapy.
    Nishizawa M; Matsuda M; Hattori J; Shiino T; Matano T; Heneine W; Johnson JA; Sugiura W
    PLoS One; 2015; 10(9):e0135941. PubMed ID: 26360259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virological response, HIV-1 drug resistance mutations and genetic diversity among patients on first-line antiretroviral therapy in N'Djamena, Chad: findings from a cross-sectional study.
    Adawaye C; Fokam J; Kamangu E; Alio HM; Chahad AM; Susin F; Moussa AM; Bertin TH; Tidjani A; Vaira D; Moutschen M
    BMC Res Notes; 2017 Nov; 10(1):589. PubMed ID: 29126456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly-sensitive allele-specific PCR testing identifies a greater prevalence of transmitted HIV drug resistance in Japan.
    Nishizawa M; Hattori J; Shiino T; Matano T; Heneine W; Johnson JA; Sugiura W
    PLoS One; 2013; 8(12):e83150. PubMed ID: 24358257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of LigAmp and an ASPCR assay for detection and quantification of K103N-containing HIV variants.
    Church JD; Towler WI; Hoover DR; Hudelson SE; Kumwenda N; Taha TE; Eshleman JR; Eshleman SH
    AIDS Res Hum Retroviruses; 2008 Apr; 24(4):595-605. PubMed ID: 18370589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-resistance mutations number and K70R or T215Y/F substitutions predict treatment resumption during guided treatment interruptions.
    Darwich L; Esteve A; Ruiz L; Paredes R; Bellido R; Cabrera C; Romeu J; Bofill M; Clotet B; Martinez-Picado J
    AIDS Res Hum Retroviruses; 2008 May; 24(5):725-32. PubMed ID: 18462084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gag P2/NC and pol genetic diversity, polymorphism, and drug resistance mutations in HIV-1 CRF02_AG- and non-CRF02_AG-infected patients in Yaoundé, Cameroon.
    Teto G; Tagny CT; Mbanya D; Fonsah JY; Fokam J; Nchindap E; Kenmogne L; Njamnshi AK; Kanmogne GD
    Sci Rep; 2017 Oct; 7(1):14136. PubMed ID: 29074854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV virologic response, patterns of drug resistance mutations and correlates among adolescents and young adults: A cross-sectional study in Tanzania.
    Rugemalila J; Kamori D; Kunambi P; Mizinduko M; Sabasaba A; Masoud S; Msafiri F; Mugusi S; Mutagonda R; Mlunde L; Amani D; Mboya E; Mahiti M; Ruhago G; Mushi J; Sambu V; Mgomella G; Jullu B; Maokola W; Njau P; Mutayoba B; Barabona G; Ueno T; Pembe A; Nagu T; Sunguya B; Aboud S
    PLoS One; 2023; 18(2):e0281528. PubMed ID: 36821538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergence of minor drug-resistant HIV-1 variants after triple antiretroviral prophylaxis for prevention of vertical HIV-1 transmission.
    Hauser A; Sewangi J; Mbezi P; Dugange F; Lau I; Ziske J; Theuring S; Kuecherer C; Harms G; Kunz A
    PLoS One; 2012; 7(2):e32055. PubMed ID: 22384138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High level of HIV-1 drug resistance mutations in patients with unsuppressed viral loads in rural northern South Africa.
    Etta EM; Mavhandu L; Manhaeve C; McGonigle K; Jackson P; Rekosh D; Hammarskjold ML; Bessong PO; Tebit DM
    AIDS Res Ther; 2017 Jul; 14(1):36. PubMed ID: 28750647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults.
    Namakoola I; Kasamba I; Mayanja BN; Kazooba P; Lutaakome J; Lyagoba F; Kapaata AA; Kaleebu P; Munderi P;
    BMC Res Notes; 2016 Dec; 9(1):515. PubMed ID: 28010730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Added Value of Next Generation over Sanger Sequencing in Kenyan Youth with Extensive HIV-1 Drug Resistance.
    Novitsky V; Nyandiko W; Vreeman R; DeLong AK; Manne A; Scanlon M; Ngeresa A; Aluoch J; Sang F; Ashimosi C; Jepkemboi E; Orido M; Hogan JW; Kantor R;
    Microbiol Spectr; 2022 Dec; 10(6):e0345422. PubMed ID: 36445146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of two HIV-1 infectors during initial antiretroviral treatment, and the emergence of phenotypic resistance in reverse transcriptase-associated mutation patterns.
    Guo W; Han J; Zhuang D; Liu S; Liu Y; Li L; Li H; Bao Z; Wang F; Li J
    Virol J; 2015 Nov; 12():187. PubMed ID: 26578099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-retroviral drug resistance-associated mutations among non-subtype B HIV-1-infected Kenyan children with treatment failure.
    Lwembe R; Ochieng W; Panikulam A; Mongoina CO; Palakudy T; Koizumi Y; Kageyama S; Yamamoto N; Shioda T; Musoke R; Owens M; Songok EM; Okoth FA; Ichimura H
    J Med Virol; 2007 Jul; 79(7):865-72. PubMed ID: 17516531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multimethod Longitudinal HIV Drug Resistance Analysis in Antiretroviral-Therapy-Naive Patients.
    Nanfack AJ; Redd AD; Bimela JS; Ncham G; Achem E; Banin AN; Kirkpatrick AR; Porcella SF; Agyingi LA; Meli J; Colizzi V; Nádas A; Gorny MK; Nyambi PN; Quinn TC; Duerr R
    J Clin Microbiol; 2017 Sep; 55(9):2785-2800. PubMed ID: 28659324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations.
    Paredes R; Marconi VC; Campbell TB; Kuritzkes DR
    J Virol Methods; 2007 Dec; 146(1-2):136-46. PubMed ID: 17662474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.
    Boender TS; Kityo CM; Boerma RS; Hamers RL; Ondoa P; Wellington M; Siwale M; Nankya I; Kaudha E; Akanmu AS; Botes ME; Steegen K; Calis JC; Rinke de Wit TF; Sigaloff KC
    J Antimicrob Chemother; 2016 Oct; 71(10):2918-27. PubMed ID: 27342546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.